Rapamycin

Synonyme: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methyle thyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-2

  • Art-Nr.:LS-1056
  • CAS Nr.:53123-88-9
  • Formel:C51H79NO13
  • Molare Masse:914,2 g/mol

Startet von 350,00 €

Gruppiert Produkte - Artikel
Anzahl Verpackungsgröße Preis SKU
250 mg
350,00 €
LS-1056.0250
500 mg
450,00 €
LS-1056.0500
1 g
775,00 €
LS-1056.1000
5 g
1.650,00 €
LS-1056.5000
Sicherheitsdatenblätter
description

Rapamycin inhibits angiogenesis - a new candidate for combination therapy!

Rapamycin, approved by the FDA for immunosuppression in transplant patients, is currently under investigation for cancer treatment. It inhibits endothelial Akt signaling, vascular changes from myrAkt1, tumor growth, and tumor vascular permeability. In mouse models a reduced tumor growth and vascular leak has been observed. These findings make rapamycin very interesting in regimens where anti-angiogenic therapy in cancer patients is desired.

references

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC,

Dvorak HF, Benjamin LE; Cancer Cell. 2006; 10(2): 159-70.

Bulk oder Großmengen-Bestellung?

Sie benötigen größere Mengen für Ihre Entwicklung oder Produktion?

Benötigen Sie weitere Informationen über dieses Produkt?

kontaktieren Sie uns

Schneller Kontakt

Bitte senden Sie mir mehr Informationen über

Produkte, die Sie auch interessieren könnten!